RT Journal Article
SR Electronic
T1 Clinical Utility of SARS-CoV-2 Whole Genome Sequencing in Deciphering Source of Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.21.20107599
DO 10.1101/2020.05.21.20107599
A1 Takenouchi, Toshiki
A1 Iwasaki, Yuka W.
A1 Harada, Sei
A1 Ishizu, Hirotsugu
A1 Uwamino, Yoshifumi
A1 Uno, Shunsuke
A1 Osada, Asami
A1 Hasegawa, Naoki
A1 Murata, Mitsuru
A1 Takebayashi, Toru
A1 Fukunaga, Koichi
A1 Saya, Hideyuki
A1 Kitagawa, Yuko
A1 Amagai, Masayuki
A1 Siomi, Haruhiko
A1 Kosaki, Kenjiro
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.21.20107599.abstract
AB The novel coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2 is a major threat to humans. Recently, we encountered two seemingly separate COVID-19 clusters in a tertiary care medical center. Whole viral genome sequencing detected the haplotype of the SARS-CoV-2 genome and the two clusters were successfully distinguished by the viral genome haplotype. Concurrently, there were nine COVID-19 patients clinically unlinked to clusters #1 or #2 that necessitated the determination of the source of infection. Such patients had similar haplotypes to those in cluster #2 but were devoid of two rare mutations characteristic to cluster #2. This suggested that these nine cases of “probable community infection” indeed had community infection and were not derived from cluster #2. Whole viral genome sequencing of SARS-CoV-2 is a powerful measure not only for monitoring the global trend of SARS-CoV-2 but also for identifying the source of infection of COVID-19 at a level of institution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementInternal research fundAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Keio University School of Medicine Ethics Committee approved the present study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe uploaded the full nucleotide sequences of our cohort to the GISAID database (https://www.gisaid.org/). https://www.gisaid.org/